PL2768524T3 - Immunoterapia oparta na pd-l1 - Google Patents
Immunoterapia oparta na pd-l1Info
- Publication number
- PL2768524T3 PL2768524T3 PL12780408.6T PL12780408T PL2768524T3 PL 2768524 T3 PL2768524 T3 PL 2768524T3 PL 12780408 T PL12780408 T PL 12780408T PL 2768524 T3 PL2768524 T3 PL 2768524T3
- Authority
- PL
- Poland
- Prior art keywords
- based immunotherapy
- immunotherapy
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170574 | 2011-10-17 | ||
| PCT/DK2012/050386 WO2013056716A1 (en) | 2011-10-17 | 2012-10-17 | Pd-l1 based immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2768524T3 true PL2768524T3 (pl) | 2022-09-19 |
Family
ID=47115103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12780408.6T PL2768524T3 (pl) | 2011-10-17 | 2012-10-17 | Immunoterapia oparta na pd-l1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9669078B2 (OSRAM) |
| EP (2) | EP2768524B1 (OSRAM) |
| JP (1) | JP6259763B2 (OSRAM) |
| CN (2) | CN113444165A (OSRAM) |
| BR (1) | BR112014009526B8 (OSRAM) |
| CA (1) | CA2850245C (OSRAM) |
| CY (1) | CY1125453T1 (OSRAM) |
| DK (1) | DK2768524T3 (OSRAM) |
| ES (1) | ES2918580T3 (OSRAM) |
| HR (1) | HRP20220924T1 (OSRAM) |
| HU (1) | HUE059406T2 (OSRAM) |
| LT (1) | LT2768524T (OSRAM) |
| PL (1) | PL2768524T3 (OSRAM) |
| PT (1) | PT2768524T (OSRAM) |
| SI (1) | SI2768524T1 (OSRAM) |
| WO (1) | WO2013056716A1 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2768524T (lt) * | 2011-10-17 | 2022-07-25 | Io Biotech Aps | Pd-l1 grindžiama imunoterapija |
| TWI676636B (zh) * | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| WO2015153969A1 (en) | 2014-04-04 | 2015-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand discovery for t cell receptors |
| EP3936145A1 (en) * | 2014-07-31 | 2022-01-12 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| JP6918333B2 (ja) * | 2014-09-17 | 2021-08-11 | 学校法人近畿大学 | 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤 |
| EP3193917B9 (en) | 2014-09-17 | 2022-02-16 | IO Biotech ApS | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof |
| IL251669B2 (en) | 2014-10-10 | 2023-02-01 | Idera Pharmaceuticals Inc | Cancer treatment using a tlr9 agonist with checkpoint inhibitors |
| US11773447B2 (en) * | 2014-11-14 | 2023-10-03 | Nanthealth Labs, Inc. | Use of circulating cell-free RNA for diagnosis and/or monitoring cancer |
| CA2985227C (en) * | 2015-05-15 | 2021-05-04 | Reber Genetics Co., Ltd. | Novel baculovirus vectors and methods of use |
| EA201890619A1 (ru) | 2015-09-02 | 2018-09-28 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| JP6924747B2 (ja) | 2015-09-16 | 2021-08-25 | アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ | Ｃ−ｃモチーフケモカイン２２（ｃｃｌ２２）またはこのフラグメントを含むワクチン組成物 |
| FI3423087T3 (fi) * | 2016-03-04 | 2023-12-15 | Io Biotech Aps | Syövän vastainen yhdistelmähoito |
| HRP20210315T1 (hr) * | 2016-03-14 | 2021-04-16 | F. Hoffmann - La Roche Ag | Oligonukleotidi za smanjenje ekspresije pd-l1 |
| BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| JP2019517544A (ja) | 2016-06-10 | 2019-06-24 | アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ | Ｃａｌｒ及びｊａｋ２ワクチン組成物 |
| EP3472180A1 (en) | 2016-06-21 | 2019-04-24 | IO Biotech APS | Pdl1 peptides for use in cancer vaccines |
| WO2018006005A1 (en) | 2016-06-30 | 2018-01-04 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2018140890A1 (en) * | 2017-01-29 | 2018-08-02 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
| CN108503691B (zh) * | 2017-02-25 | 2021-07-23 | 复旦大学 | 一种人pd-l1蛋白高亲和性肽及其应用 |
| WO2018160538A1 (en) | 2017-02-28 | 2018-09-07 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| US11357842B2 (en) | 2017-03-17 | 2022-06-14 | Vaximm Ag | PD-L1 targeting DNA vaccine for cancer immunotherapy |
| US20200299401A1 (en) * | 2017-11-24 | 2020-09-24 | Io Biotech Aps | Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc) |
| WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| JP2021506883A (ja) | 2017-12-21 | 2021-02-22 | メルサナ セラピューティクス インコーポレイテッド | ピロロベンゾジアゼピン抗体結合体 |
| US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
| FR3086534B1 (fr) * | 2018-10-01 | 2020-11-06 | Univ Bordeaux | Methode pour traiter une infection par le virus de l'immunodeficience humaine |
| EP3873534A1 (en) | 2018-10-29 | 2021-09-08 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| CN109593135B (zh) * | 2018-12-29 | 2021-01-15 | 百奥赛图江苏基因生物技术有限公司 | 抗人pd-l1单克隆抗体及其应用 |
| WO2020181402A1 (zh) * | 2019-03-10 | 2020-09-17 | 胡西木 | 一种抗肿瘤多肽及其应用 |
| CN113249447A (zh) * | 2019-04-26 | 2021-08-13 | 嘉兴允英医学检验有限公司 | 一种pd-l1表达水平检测的方法和试剂盒 |
| BR112022005044A2 (pt) * | 2019-09-17 | 2022-07-05 | Ohio State Innovation Foundation | Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento |
| WO2021208106A1 (zh) * | 2020-04-18 | 2021-10-21 | 北京泽勤生物医药有限公司 | 一种治疗自身免疫病的融合肽 |
| CU24705B1 (es) * | 2020-10-22 | 2024-06-11 | Ct Ingenieria Genetica Biotecnologia | Antígeno quimérico que comprende el dominio extracelular de pd-l1 |
| GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| EP4340948A4 (en) * | 2021-05-17 | 2025-03-12 | Wisconsin Alumni Research Foundation (WARF) | SYNTHETIC PROTEIN TO INDUCE IMMUNE TOLERANCE |
| KR102421307B1 (ko) * | 2021-11-19 | 2022-07-14 | 을지대학교 산학협력단 | 암 발생 및 성장 억제를 위한 신규 항암 백신 조성물 및 그를 이용한 백신화 방법 |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| CN114702569B (zh) * | 2022-05-25 | 2023-01-10 | 深圳吉诺因生物科技有限公司 | Pd-l1相关疫苗及其应用 |
| WO2025043075A1 (en) * | 2023-08-24 | 2025-02-27 | The Johns Hopkins University | Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury |
| EP4527849A1 (en) | 2023-09-19 | 2025-03-26 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Hla-independent antigen binders, such as t-cell receptors, against pd-l1 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| JP2003513662A (ja) * | 1999-11-09 | 2003-04-15 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | １５個のヒト分泌タンパク質 |
| EP2388590A1 (en) * | 2001-04-02 | 2011-11-23 | Dana Farber Cancer Institute | PD-1, a receptor for B7-4, and uses thereof |
| AU2002258941A1 (en) * | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| EP1537878B1 (en) * | 2002-07-03 | 2010-09-22 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| WO2004056875A1 (en) * | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| AU2007342338A1 (en) * | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies |
| WO2009026472A1 (en) | 2007-08-21 | 2009-02-26 | The General Hospital Corporation | Methods for inducing tolerance |
| US20110159023A1 (en) * | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| JP6066732B2 (ja) * | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
| LT2768524T (lt) * | 2011-10-17 | 2022-07-25 | Io Biotech Aps | Pd-l1 grindžiama imunoterapija |
-
2012
- 2012-10-17 LT LTEPPCT/DK2012/050386T patent/LT2768524T/lt unknown
- 2012-10-17 SI SI201232003T patent/SI2768524T1/sl unknown
- 2012-10-17 EP EP12780408.6A patent/EP2768524B1/en active Active
- 2012-10-17 JP JP2014536116A patent/JP6259763B2/ja active Active
- 2012-10-17 PL PL12780408.6T patent/PL2768524T3/pl unknown
- 2012-10-17 US US14/352,407 patent/US9669078B2/en active Active
- 2012-10-17 HR HRP20220924TT patent/HRP20220924T1/hr unknown
- 2012-10-17 DK DK12780408.6T patent/DK2768524T3/da active
- 2012-10-17 HU HUE12780408A patent/HUE059406T2/hu unknown
- 2012-10-17 WO PCT/DK2012/050386 patent/WO2013056716A1/en not_active Ceased
- 2012-10-17 EP EP22163851.3A patent/EP4079319A1/en active Pending
- 2012-10-17 BR BR112014009526A patent/BR112014009526B8/pt active IP Right Grant
- 2012-10-17 ES ES12780408T patent/ES2918580T3/es active Active
- 2012-10-17 CN CN202110437930.3A patent/CN113444165A/zh active Pending
- 2012-10-17 CN CN201280050948.7A patent/CN103917243B/zh active Active
- 2012-10-17 PT PT127804086T patent/PT2768524T/pt unknown
- 2012-10-17 CA CA2850245A patent/CA2850245C/en active Active
-
2022
- 2022-08-02 CY CY20221100528T patent/CY1125453T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014009526B1 (pt) | 2021-07-13 |
| BR112014009526B8 (pt) | 2023-01-17 |
| WO2013056716A1 (en) | 2013-04-25 |
| CN103917243A (zh) | 2014-07-09 |
| SI2768524T1 (sl) | 2022-09-30 |
| EP2768524B1 (en) | 2022-05-04 |
| US20140242101A1 (en) | 2014-08-28 |
| CN113444165A (zh) | 2021-09-28 |
| BR112014009526A2 (pt) | 2017-05-09 |
| DK2768524T3 (da) | 2022-07-04 |
| JP6259763B2 (ja) | 2018-01-10 |
| CY1125453T1 (el) | 2025-05-09 |
| HRP20220924T1 (hr) | 2022-10-28 |
| EP2768524A1 (en) | 2014-08-27 |
| US9669078B2 (en) | 2017-06-06 |
| CA2850245C (en) | 2020-04-28 |
| CN103917243B (zh) | 2021-05-11 |
| ES2918580T3 (es) | 2022-07-19 |
| JP2014534202A (ja) | 2014-12-18 |
| PT2768524T (pt) | 2022-07-05 |
| HUE059406T2 (hu) | 2022-11-28 |
| LT2768524T (lt) | 2022-07-25 |
| CA2850245A1 (en) | 2013-04-25 |
| EP4079319A1 (en) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2768524T (lt) | Pd-l1 grindžiama imunoterapija | |
| DK3424953T3 (en) | Terapeutiske antistoffer | |
| DK2691417T4 (en) | Antistof fc-varianter | |
| PL3434695T3 (pl) | Ulepszona immunoterapia | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| EP2755962A4 (en) | AZAINDAZOLES | |
| EP2715659A4 (en) | ABOUT FEED | |
| EP2723631A4 (en) | QUADFOILER | |
| EP2673635A4 (en) | IMMUNOTHERAPY THROUGH APOE | |
| EP2776444A4 (en) | dihydropteridinones | |
| GB201117538D0 (en) | Methods | |
| GB201120860D0 (en) | Cancer immunotherapy | |
| EP2695208A4 (en) | MICRO-THERMOCOUPLE | |
| GB201301300D0 (en) | No details | |
| GB201119167D0 (en) | Novel bachteriophages | |
| ZA201403228B (en) | Heterocyclypyri(mi)dinylpyrazole | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201100001D0 (en) | TidySqueeze2 | |
| AU4540P (en) | BUNNAN Baloskion tetraphyllum | |
| AU5171P (en) | Sunparamiho Mandevilla xamabilis | |
| AU5031P (en) | BESYS Beschorneria yuccoides | |
| AU5026P (en) | Goldstrike Agapanthus inapertus | |
| GB201303586D0 (en) | No details | |
| GB201216278D0 (en) | No details |